GB2226759A - Pharmaceutical compositions containing lysine - Google Patents
Pharmaceutical compositions containing lysine Download PDFInfo
- Publication number
- GB2226759A GB2226759A GB8900048A GB8900048A GB2226759A GB 2226759 A GB2226759 A GB 2226759A GB 8900048 A GB8900048 A GB 8900048A GB 8900048 A GB8900048 A GB 8900048A GB 2226759 A GB2226759 A GB 2226759A
- Authority
- GB
- United Kingdom
- Prior art keywords
- aminoethanol
- hydroxylysine
- lysine
- drugs according
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims description 7
- 239000004472 Lysine Substances 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 9
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 9
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 9
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 3
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical class [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3744542A DE3744542B4 (de) | 1987-12-30 | 1987-12-30 | Pharmazeutische Verwendung von L-δ-Hydroxylysin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB8900048D0 GB8900048D0 (en) | 1989-03-01 |
| GB2226759A true GB2226759A (en) | 1990-07-11 |
Family
ID=6343857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8900048A Withdrawn GB2226759A (en) | 1987-12-30 | 1989-01-04 | Pharmaceutical compositions containing lysine |
Country Status (3)
| Country | Link |
|---|---|
| CH (1) | CH678490A5 (enrdf_load_stackoverflow) |
| DE (1) | DE3744542B4 (enrdf_load_stackoverflow) |
| GB (1) | GB2226759A (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3912477A1 (de) * | 1989-04-15 | 1990-10-18 | Mueller Robert Dr | Aeusserlich anzuwendendes praeparat und seine verwendung |
| IT1407715B1 (it) * | 2010-06-18 | 2014-04-30 | Alphrema Srl | Composizioni ad uso topico per la profilassi ed il trattamento igienico di alcune problematiche di patologia ano-rettale, come emorroidi, ragadi, ascessi e fistole. |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1210968A (en) * | 1967-10-11 | 1970-11-04 | Far Eastern Detailers Ltd | Improvements in or relating to the treatment of gastric ailments |
| GB1219869A (en) * | 1968-07-24 | 1971-01-20 | Farmaceutici Italia | Stabilized estrogen sulphate salts |
| GB1381649A (en) * | 1971-10-13 | 1975-01-22 | Tixier G | Medicine comprising lysine by-products |
| GB1399887A (en) * | 1971-06-10 | 1975-07-02 | Prockop D J | Composition and methods for controlling collagen synthesis |
| EP0163111A2 (en) * | 1984-04-28 | 1985-12-04 | Kyowa Hakko Kogyo Co., Ltd. | Method for solubilization of interferon |
| GB2181647A (en) * | 1985-10-01 | 1987-04-29 | Jean Morelle | Compositions based on lysine and arginine salts |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3728852C2 (de) * | 1987-08-28 | 2003-06-18 | Wilhelm Hoerrmann | Arzneimittel zur Tumortherapie |
-
1987
- 1987-12-30 DE DE3744542A patent/DE3744542B4/de not_active Expired - Fee Related
-
1988
- 1988-12-21 CH CH4684/88A patent/CH678490A5/de not_active IP Right Cessation
-
1989
- 1989-01-04 GB GB8900048A patent/GB2226759A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1210968A (en) * | 1967-10-11 | 1970-11-04 | Far Eastern Detailers Ltd | Improvements in or relating to the treatment of gastric ailments |
| GB1219869A (en) * | 1968-07-24 | 1971-01-20 | Farmaceutici Italia | Stabilized estrogen sulphate salts |
| GB1399887A (en) * | 1971-06-10 | 1975-07-02 | Prockop D J | Composition and methods for controlling collagen synthesis |
| GB1381649A (en) * | 1971-10-13 | 1975-01-22 | Tixier G | Medicine comprising lysine by-products |
| EP0163111A2 (en) * | 1984-04-28 | 1985-12-04 | Kyowa Hakko Kogyo Co., Ltd. | Method for solubilization of interferon |
| GB2181647A (en) * | 1985-10-01 | 1987-04-29 | Jean Morelle | Compositions based on lysine and arginine salts |
Non-Patent Citations (3)
| Title |
|---|
| JP-57/67513 A2 * |
| JP-58/177995 A2 * |
| The Extra Pharmacopoeia (MARTINDALE),28th Ed. p.56 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8900048D0 (en) | 1989-03-01 |
| DE3744542A1 (de) | 1989-07-13 |
| CH678490A5 (enrdf_load_stackoverflow) | 1991-09-30 |
| DE3744542B4 (de) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4626536A (en) | Compositions for combatting toxaemia | |
| US4496545A (en) | Nonapeptide for treating addictive drug withdrawal conditions | |
| DE69713485T2 (de) | Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie | |
| ES2137948T3 (es) | Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina. | |
| EP0139534B1 (en) | Compositions for the prophylactic treatment of osteitis and osteomyelitis | |
| RU94046316A (ru) | Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| JPS5998015A (ja) | 免疫賦活剤 | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| AU693076B2 (en) | Arsenic medicaments for the treatment of chronic fatigue syndrome | |
| US4861587A (en) | Use of TNF for the prevention or treatment of radiation damage | |
| US4882336A (en) | Method and pharmaceutical composition for treating leukoencephalitic demyelinization clinical patterns of autoimmune origin, particularly multiple sclerosis | |
| GB2226759A (en) | Pharmaceutical compositions containing lysine | |
| US3852453A (en) | Method of enhancing vincamine compositions | |
| KR890004705A (ko) | 항바이러스성 제제 | |
| US5665371A (en) | Medicines which contain derivatives of proline or hydroxyproline | |
| Kirby | Vancomycin therapy of staphylococcal infections | |
| US4686225A (en) | Vinpocetine for pulmonary hemorrhage and edema | |
| US3873709A (en) | Method of treating psychosis | |
| US5955498A (en) | Agent for prophylaxis and therapy of diseases | |
| CA1170184A (en) | Psychotropic drugs | |
| Massimo et al. | Control of pain with sublingual buprenorphine in children with cancer | |
| US4062974A (en) | Method for treating drepanocytosis | |
| GB2064958A (en) | Medicaments containing aspirin | |
| Stratigos et al. | Treatment of gonorrhoea with spectinomycin hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |